MS review: diet and exercise links need more evidence
By MS Buddy ·
Summarized from Neurobiology of disease, Nov 2026 · PubMed. AI-generated summary. Not medical advice.
Review · People with MS, healthy people, and experimental models
Research by Giuseppe Maccarrone, Fabio Buttari and 8 colleagues at IRCCS Neuromed and the University of Rome Tor Vergata in Italy.
Do diet and exercise affect MS through the body's own cannabis-like signals?
Key Takeaway
This review found no direct evidence that diet or exercise improves MS through the body's own cannabis-like signaling system.

What They Found
Cannabis-based medicines have their clearest established role in easing MS symptoms, particularly muscle stiffness and related symptoms. Evidence that they affect nerve damage or inflammation comes mainly from laboratory and animal studies. Exercise can raise levels of a natural cannabis-like signal in healthy people. Diet and gut microbes may also affect this signaling system, but their role in MS remains uncertain. The review did not establish that changing these signals through lifestyle changes slows MS.
Who Should Care and Why
This review examined evidence from people, laboratory studies, and animal studies relevant to MS. It concerns people with MS interested in diet, exercise, and microbes living in the gut. However, much of the lifestyle evidence came from healthy people or experimental models rather than people with MS. The review separates established symptom relief from possible effects that still need testing. It presents lifestyle-related ideas alongside medicines that slow MS, not as proven ways to change the disease.
Important Considerations
This was a review of existing evidence, and the abstract gives no total number of participants. You cannot tell from this review whether diet or exercise improves MS through the body's own cannabis-like signals. Direct studies in people with MS are needed to test these proposed links.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Neurobiology of disease by et al.. Reproduced from the PubMed record.
Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by neuroinflammation, inflammatory synaptopathy, and progressive neurodegeneration. Increasing evidence identifies the endocannabinoid system (ECS) as a regulator of synaptic transmission, neuroinflammatory tone, and neuroplasticity; however, its translational relevance in people with MS remains incompletely established. Cannabinoid-based compounds have their most established clinical role in symptomatic treatment, particularly for residual symptoms within the spasticity-plus syndrome, whereas effects on excitotoxicity, microglial activation, and neuroinflammation are supported mainly by mechanistic and preclinical evidence. Lifestyle-related factors, including physical activity, diet, and gut microbiome composition, have been associated with ECS-related signaling changes in healthy individuals and experimental models, but direct evidence of ECS-mediated effects in MS remains limited. Physical activity can increase circulating levels of the endocannabinoid anandamide in healthy individuals, while dietary components may influence ECS-related pathways through polyunsaturated fatty acids and phytochemicals; however, direct ECS-mediated clinical effects of either intervention in MS have not been demonstrated. Experimental evidence also supports bidirectional interactions between the gut microbiome and the ECS, although their clinical relevance in MS remains uncertain. Overall, these findings support a biologically plausible, hypothesis-generating framework linking lifestyle factors and ECS-related pathways alongside disease modifying treatments, without demonstrating causal mediation or disease-modifying efficacy. This review integrates preclinical and clinical evidence to distinguish established symptomatic effects from biological plausibility and indirect associations, and highlights priorities for prospective validation and personalized multimodal MS management.
Categories
Explore more research
Related MS research

11/20/2026
A review looks at changes in how the body uses tryptophan (a building block of proteins) in MS and o
Read More
11/19/2026
Five people with MS received engineered immune cells. Spinal fluid immune changes were seen, but saf
Read More
11/19/2026
A review of 50 studies found wide differences in MS rates across the Americas. MS became more common
Read More
11/20/2026
A study of online MS medication discussions found two main styles: sharing personal experiences and
Read More
11/20/2026
A small study followed brain connections and thinking in early MS over 10 months. Patterns differed
Read More
11/20/2026
A global study including childhood MS found rising rates and disability from rare childhood brain an
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
